Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Tanvex names a CEO, while Simtra appoints a chief commercial officer and Enzene adds a senior vice president. Welcome to the fortnightly roundup brought to you by BioProcess Insider.
Deal-Making
The pharmaceutical giant will seek to develop novel vaccines to improve the lives of pets.
Seeking to bolster its CDMO business, Bora Pharmaceuticals is acquiring an approximate 30.5% stake in Taiwanese drug maker Tanvex BioPharma.
Facilities & Capacity
The acquisition will increase manufacturing capacity, strengthen commercial service offerings, and expedite the delivery of sterile injectable drug products for clinical and commercial markets, the firm said.
Merck KGaA’s life science business is the first company to receive such certification for pharmaceutical auxiliary materials (PAMs).
Global Markets
CDMO KBI Biopharma says a lack of capacity demand drove the U-turn on mammalian manufacturing, but the Geneva site will continue to offer other bioproduction services.
The organization will work with vaccine manufacturers to bring much-need doses to Africa.
Regulations
An expert touts the value of written guidance and Explainable AI for establishing industry-wide trust.
Industry will have to rethink GMP regulations to accommodate AI and ML, says a panel of experts.
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Therapeutic Class
The pharmaceutical giant will seek to develop novel vaccines to improve the lives of pets.
The companies say they have capacity to produce 200 million doses and hope to distribute the low-cost vaccine globally to low- and middle-income countries (LMICs).
Upstream & Downstream Processing
Rentschler’s LVV toolbox will offer advanced bioreactor systems, analytical methods for thorough characterization and quality control, and an HEK293 cell line for consistent yields, the firm said.
Experts from Terumo share insights on developing and manufacturing advanced therapies for non-oncological indications.